Document and Entity Information
Document and Entity Information | Nov. 19, 2020 |
Cover [Abstract] | |
Document Type | 8-K/A |
Document Period End Date | Nov. 19, 2020 |
Entity Registrant Name | F-STAR THERAPEUTICS, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-37718 |
Entity Tax Identification Number | 52-2386345 |
Entity Address, Address Line One | Eddeva B920 Babraham Research Campus |
Entity Address, City or Town | Cambridge |
Entity Address, Country | GB |
Entity Address, Postal Zip Code | CB22 3AT |
Country Region | 44 |
City Area Code | 1223 |
Local Phone Number | 497400 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Amendment Description | On November 20, 2020, F-star Therapeutics, Inc., formerly known as “Spring Bank Pharmaceuticals, Inc.” (the “Company”), completed its business combination (the “Transaction”) with F-star Therapeutics Limited (“F-star”) in accordance with the terms of the Share Exchange Agreement, dated as of July 29, 2020 (the “Exchange Agreement”), by and among the Company, F-star and the holders of issued shares in the capital stock of F-star and the holders of convertible notes of F-star each as set forth therein (each a “Seller”, and collectively with holders of F-star securities who subsequently became parties to the Exchange Agreement, the “Sellers”). Pursuant to the Exchange Agreement, each ordinary share of F-star outstanding immediately prior to the closing of the Transaction (the “Closing”) was exchanged by the Seller that owned such F-star shares for such number of duly authorized, validly issued, fully paid and non-assessable shares of Company common stock as was equal to the exchange ratio formula determined pursuant to the Exchange Agreement (the “Exchange Ratio”), rounded to the nearest whole share of Company common stock (after aggregating all fractional shares of Company common stock issuable to such Seller) and, as a result, the Company became F-star Therapeutics, Inc. Also on November 20, 2020, in connection with, and prior to completion of, the Transaction, the Company effected a 1-for-4 reverse stock split of its common stock (the “Reverse Stock Split”) and, following the completion of the Transaction, changed its name to “F-star Therapeutics, Inc.” Following the completion of the Transaction, the business of the Company became the business conducted by F-star, which is a clinical stage immuno-oncology company focused on cancer treatment through its proprietary tetravalent bispecific antibody programs. Unless otherwise noted, all references to share amounts in this Current Report on Form 8-K reflect the Reverse Stock Split. On November 20, 2020, the Company filed a Current Report on Form 8-K (the “Original Form 8-K”) reporting, among other items, the consummation of the Transaction. This amendment amends the Original Form 8-K to provide certain historical and pro-forma financial information required by Items 9.01(a) and 9.01(b) of Form 8-K, respectively. Such financial information as required by Items 9.01(a) and 9.01(b) was excluded from the Original Form 8-K in reliance on the instructions to such Items. Except as set forth in this amendment to the Original Form 8-K, no other changes are being made to the Original Form 8-K. |
Entity Information, Former Legal or Registered Name | Spring Bank Pharmaceuticals, Inc. |
Amendment Flag | true |
Entity Central Index Key | 0001566373 |
Title of 12(b) Security | Common Stock, $0.0001 par value |
Trading Symbol | FSTX |
Security Exchange Name | NASDAQ |